Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OVX836
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: European Innovation Council
Deal Size: $34.0 million Upfront Cash: Undisclosed
Deal Type: Funding July 08, 2020
Details:
The grant willsupport the completion of the Company’s Phase 2a immunogenicity clinical trial for OVX836, its lead universal flu vaccine candidate and the early discovery phase for its universal coronavirus vaccine program.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
